tradingkey.logo

Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight

ReutersJan 13, 2026 12:10 AM

- Amgen AMGN.O said on Monday a 24-week study of monthly doses of its experimental obesity drug MariTide in people with type 2 diabetes showed "robust and clinically meaningful" reduction in both blood sugar and weight.

In a 52-week extension study, a large majority of participants who received a lower monthly dose or a quarterly dose maintained the weight loss achieved during the initial phase 2 trial, the company said.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI